Drug intelligence / Profile preview

VRC-HIVDNA044-00-VP

Development stage: Phase 1
Lead developer: Vaccine Research Center
Modality: DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

VRC-HIVDNA044-00-VP is an experimental multiclade DNA vaccine developed by the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID). The vaccine is designed to prevent HIV-1 infection by eliciting broad cellular (T-cell) and humoral (B-cell) immune responses. It typically consists of six distinct mammalian expression plasmids encoding various HIV-1 antigens: a Gag-Pol-Nef fusion protein and Envelope (Env) glycoproteins from clades A, B, and C. In clinical development, VRC-HIVDNA044-00-VP has been evaluated primarily as a priming agent in heterologous prime-boost regimens, followed by boosting with viral vector vaccines such as recombinant adenovirus serotype 5 (rAd5) or serotype 35 (rAd35) to enhance the magnitude and breadth of the immune response.

Other names: VRC multiclade HIV-1 DNA vaccineVRC-HIVDNA044VRC-HIVDNA-044VRC-HIVDNA 044

Targets

Human immunodeficiency virus type 1 reverse transcriptaseNef (HIV-1 Nef)gp41 (Human immunodeficiency virus type 1 glycoprotein 41)Gag (HIV-1 Gag polyprotein)

Beyond the preview

Go deeper on VRC-HIVDNA044-00-VP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VRC-HIVDNA044-00-VP.

Explore the full profile